Comparative Pharmacology
Head-to-head clinical analysis: CALCIPARINE versus ORGARAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPARINE versus ORGARAN.
CALCIPARINE vs ORGARAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unfractionated heparin (UFH) potentiates antithrombin III (ATIII) activity, leading to inhibition of factor Xa and thrombin (factor IIa). It also binds to heparin cofactor II, inhibits platelet aggregation, and increases vascular permeability.
Danaparoid is a low molecular weight heparinoid that exerts its anticoagulant effect by inhibiting factor Xa and, to a lesser extent, factor IIa (thrombin) through binding to antithrombin III and heparin cofactor II.
5000 IU subcutaneously twice daily for prophylaxis; 5000 IU intravenous bolus followed by 800-1000 IU/hour continuous intravenous infusion for treatment.
Adults: Initial intravenous bolus of 2500 IU (anti-Xa), followed by continuous intravenous infusion of 400 IU/h for 2 hours, then 300 IU/h for 2 hours, then 200 IU/h for 5 days; or subcutaneous injection of 750 IU twice daily. Dose adjusted to maintain anti-Xa levels of 0.5-1.0 IU/mL.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (subcutaneous) after a 5000 IU dose. With therapeutic doses (e.g., 15,000 IU/24h), half-life may prolong to 2-3 hours. Clinical context: Half-life is dose-dependent and increases with heparin clearance saturation.
Terminal elimination half-life: 18-25 hours (mean ~19 hours) in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe renal failure, CrCl <30 mL/min).
Primarily renal, with 40-60% of the dose excreted unchanged in urine. Minor biliary/fecal elimination (<10%).
Renal: 40-50% as unchanged drug; biliary/fecal: minimal; small amount metabolized via desulfation and N-acetylation.
Category C
Category C
Anticoagulant
Anticoagulant